How to buy Five Prime Therapeutics stock | 20.83

Five Prime Therapeutics, Inc is a biotechnology business based in the US. Five Prime Therapeutics shares (FPRX) are listed on the NASDAQ and all prices are listed in US Dollars. Five Prime Therapeutics employs 87 staff and has a trailing 12-month revenue of around USD$18 million.

How to buy shares in Five Prime Therapeutics

1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
3. Search for Five Prime Therapeutics. Find the stock by name or ticker symbol: FPRX. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Five Prime Therapeutics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. At last close price of USD$20.83, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Five Prime Therapeutics, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of Five Prime Therapeutics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

How has coronavirus impacted Five Prime Therapeutics's share price?

Since the stock market crash in March caused by coronavirus, Five Prime Therapeutics's share price has had significant positive movement.

Its last market close was USD$20.83, which is 74.27% up on its pre-crash value of USD$5.36 and 1,090.29% up on the lowest point reached during the March crash when the shares fell as low as USD$1.75.

If you had bought USD$1,000 worth of Five Prime Therapeutics shares at the start of February 2020, those shares would have been worth USD$468.08 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$4,028.94.

Five Prime Therapeutics share price

Use our graph to track the performance of FPRX stocks over time.

Five Prime Therapeutics shares at a glance

• Key figures

Information last updated 2020-10-20.

Latest market close	USD$20.83
52-week range	USD$1.75 - USD$7.34
50-day moving average	USD$4.6059
200-day moving average	USD$4.6952
Wall St. target price	USD$8.83
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	USD$-4.486

Buy Five Prime Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

Is it a good time to buy Five Prime Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Five Prime Therapeutics, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Five Prime Therapeutics price performance over time

Historical closes compared with the close of $20.83 from 2020-11-16

1 week (2020-11-23)	19.30%
1 month (2020-10-30)	356.80%
3 months (2020-08-28)	379.95%
6 months (2020-05-29)	293.02%

1 year (2019-11-29)	431.38%
2 years (2018-11-30)	62.23%
3 years (2017-11-30)	-20.95%
5 years (2015-11-30)	-45.83%

Is Five Prime Therapeutics under- or over-valued?

Valuing Five Prime Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Five Prime Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Five Prime Therapeutics's PEG ratio

Five Prime Therapeutics's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.14. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Five Prime Therapeutics's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Five Prime Therapeutics financials

Revenue TTM	USD$18 million
Gross profit TTM	USD$-92,976,000
Return on assets TTM	-27.73%
Return on equity TTM	-63.99%
Profit margin	0%
Book value	$3.38
Market capitalisation	USD$219.8 million

TTM: trailing 12 months

Shorting Five Prime Therapeutics shares

There are currently 1.7 million Five Prime Therapeutics shares held short by investors – that's known as Five Prime Therapeutics's "short interest". This figure is 3.6% up from 1.7 million last month.

There are a few different ways that this level of interest in shorting Five Prime Therapeutics shares can be evaluated.

Five Prime Therapeutics's "short interest ratio" (SIR)

Five Prime Therapeutics's "short interest ratio" (SIR) is the quantity of Five Prime Therapeutics shares currently shorted divided by the average quantity of Five Prime Therapeutics shares traded daily (recently around 303774.60035524). Five Prime Therapeutics's SIR currently stands at 5.63. In other words for every 100,000 Five Prime Therapeutics shares traded daily on the market, roughly 5630 shares are currently held short.

However Five Prime Therapeutics's short interest can also be evaluated against the total number of Five Prime Therapeutics shares, or, against the total number of tradable Five Prime Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Five Prime Therapeutics's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 Five Prime Therapeutics shares in existence, roughly 50 shares are currently held short) or 0.0613% of the tradable shares (for every 100,000 tradable Five Prime Therapeutics shares, roughly 61 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Five Prime Therapeutics.

Find out more about how you can short Five Prime Therapeutics stock.

Five Prime Therapeutics share dividends

We're not expecting Five Prime Therapeutics to pay a dividend over the next 12 months.

Five Prime Therapeutics share price volatility

Over the last 12 months, Five Prime Therapeutics's shares have ranged in value from as little as $1.75 up to $7.34. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Five Prime Therapeutics's is 2.5389. This would suggest that Five Prime Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Five Prime Therapeutics overview

Five Prime Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of innovative protein therapeutics. The company's product candidates comprise Bemarituzumab, an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, which is in Phase 3 clinical trials to treat patients with gastric or gastroesophageal junction and GEJ cancer; and FPA150, a CD8 T cell checkpoint inhibitor antibody that is in Phase 1a/1b clinical trial that targets B7-H4 in various cancers, as well as FPT155, a soluble CD80 fusion protein, which is in Phase 1a/1b clinical trial that enhances co-stimulation of T cells through CD28. Its product candidates also include Cabiralizumab, an antibody that inhibits colony stimulating factor-1 receptor that is in Phase Ia/Ib clinical trials for the treatment of various cancers in combination with Opdivo. The company's BMS-986258, an anti-T cell immunoglobulin and mucin domain-3 antibody, which is in Phase 1/2 clinical trial as a single agent and in combination with Opdivo in patients with advanced malignant tumors. It has license and collaboration agreements with Bristol-Myers Squibb Company, GlaxoSmithKline LLC, INBRX 110 LP, UCB Pharma S.A., and Zai Lab (Shanghai) Co., Ltd.; and license agreements with Galaxy Biotech, LLC, BioWa, Inc. and Lonza Sales AG. The company was founded in 2001 and is headquartered in South San Francisco, California.

Frequently asked questions

• What percentage of Five Prime Therapeutics is owned by insiders or institutions?

  Currently 3.061% of Five Prime Therapeutics shares are held by insiders and 73.548% by institutions.

• How many people work for Five Prime Therapeutics?

  Latest data suggests 87 work at Five Prime Therapeutics.

• When does the fiscal year end for Five Prime Therapeutics?

  Five Prime Therapeutics's fiscal year ends in December.

• Where is Five Prime Therapeutics based?

  Five Prime Therapeutics's address is: 111 Oyster Point Boulevard, South San Francisco, CA, United States, 94080

• What is Five Prime Therapeutics's ISIN number?

  Five Prime Therapeutics's international securities identification number is: US33830X1046

• What is Five Prime Therapeutics's CUSIP number?

  Five Prime Therapeutics's Committee on Uniform Securities Identification Procedures number is: 33830X104